UC-101

N/A

Report date: 2025/08/22 10:16:57

Base Information

Drug NameUC-101
Drug Alias NameUC101UC-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsGraft vs Host DiseasePrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesUcello Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUcello Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseasePrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A